Illumina, Inc. (ILMN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed signals: positive EPS growth, cost management, and clinical market expansion, but offset by China headwinds and lack of specific future guidance. Sequencing consumables and instruments showed growth, but research markets remain cautious. The Q&A highlighted uncertainties in regulatory issues, competition, and research funding. Despite raised revenue and EPS guidance, the lack of clarity for 2026, especially in China, tempers optimism. Overall, the sentiment is balanced, leading to a neutral prediction for the stock price movement.
Key Financial Performance
Total Revenue $1.08 billion, flat year-over-year globally, but grew approximately 2% year-over-year excluding China. The growth was driven by the NovaSeq X transition and strong performance in clinical markets.
Non-GAAP Operating Margin 24.5%, expanded by 190 basis points year-over-year. This reflects increased operating leverage from an improved cost structure.
Non-GAAP Diluted EPS $1.34, grew $0.20 year-over-year, reflecting an 18% increase. This was driven by strong revenue performance and cost management.
Sequencing Consumables Revenue $747 million, flat year-over-year globally, but up about 3% excluding China. Growth was driven by high-throughput volumes and clinical market expansion, offset by declines in research and applied markets.
Sequencing Instruments Revenue $107 million, up approximately 3% year-over-year globally and 6% excluding China. Growth was driven by the adoption of the MiSeq 100 in the low-throughput space.
Greater China Revenue $52 million, reflecting a decline due to export restrictions on instruments.
Non-GAAP Operating Expenses $484 million, down approximately 6% year-over-year, reflecting cost reduction programs while prioritizing growth investments.
Free Cash Flow $253 million, reflecting strong cash flow provided by operations and controlled capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NovaSeq X: Achieved milestones with over 75% of high-throughput gigabases shipped and 50% of high-throughput revenue transitioned to the NovaSeq X platform. Placed over 55 instruments in Q3, exceeding goals. Consumables revenue growth accelerated, driven by clinical demand.
Illumina Protein Prep: Launched a proteomics assay capable of measuring up to 9,500 proteins per sample with consistent results in 2.5 days. Integrates with Dragon and Illumina Complete multiomics software suite.
5-base solution: Introduced an integrated library prep and software offering that reads genetic variances and DNA methylation simultaneously, reducing complexity and cost.
China Market: Revenue came in ahead of guidance despite export restrictions. Received approval to manufacture select instruments locally in China, marking progress but not a long-term resolution.
Clinical Market: Continued acceleration with high single-digit growth in sequencing consumables revenue. Driven by new assay approvals, positive reimbursement decisions, and demand for sequencing-intensive tests.
Revenue Growth: Total revenue of $1.08 billion, up 2% year-over-year excluding China. Non-GAAP operating margin expanded to 24.5%, and diluted EPS grew to $1.34.
Cost Reduction: Operating expenses reduced by 6% year-over-year due to multiyear cost reduction programs.
Multiomics Expansion: Progressed with the acquisition of SomaLogic, expected to close in 2026. Launched new products like Illumina Protein Prep and 5-base solution to expand multiomics capabilities.
BioInsight Initiative: Introduced BioInsight to accelerate genomic and multiomics data use in drug discovery and research, focusing on large-scale data generation partnerships and AI-enabled services.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Funding Uncertainty: Research labs are managing spending carefully due to regulatory and funding uncertainty, which could impact demand for sequencing consumables and instruments.
Export Restrictions in China: Ongoing export restrictions in China have negatively impacted instrument sales and overall revenue in the region, with no long-term resolution yet achieved.
Pricing Dynamics: Pricing headwinds tied to the NovaSeq X transition are affecting revenue, particularly in research and applied markets.
Economic Conditions in Research Markets: Muted growth in research markets due to economic conditions and funding challenges is limiting demand for sequencing products.
Tariffs Impacting Gross Margins: Tariffs have reduced gross margins by approximately 220 basis points year-over-year, impacting profitability.
Strategic Partnership Revenue Timing: Delays in strategic partnership revenues have led to lower-than-expected service revenue.
Dependence on Clinical Market: The company’s near-term revenue growth is heavily reliant on the clinical market, which could pose risks if demand slows or regulatory changes occur.
China Revenue Decline: Revenue in Greater China has declined significantly due to export restrictions, impacting overall financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company raised its total full-year 2025 outlook, expecting high single-digit revenue growth by 2026 and beyond. Clinical markets are the primary driver of revenue growth, with NovaSeq X volumes offsetting pricing headwinds. Research markets are expected to stabilize, contributing to growth.
Operating Margins: Illumina expects to achieve 20% non-GAAP operating margins by 2027, excluding Greater China.
China Market: Revenue from Greater China is projected to be approximately $220 million for 2025, with $33 million expected in Q4 2025. The company has received approval to manufacture select instruments locally in China, marking progress despite ongoing export restrictions.
NovaSeq X Transition: The transition to NovaSeq X is progressing well, with 75% of high-throughput gigabases shipped and 50% of high-throughput revenue already transitioned to the X platform. This transition is expected to drive continued revenue growth in 2026 and beyond.
Multiomics Expansion: Illumina plans to launch multiomics products in 2026, including Illumina Protein Prep and a 5-base solution. These launches are expected to contribute to growth as research markets recover.
Clinical Market Dynamics: Clinical demand is expected to remain strong, driven by new assay approvals, positive reimbursement decisions, and growing use of sequencing-intensive applications. Business with the largest customers is projected to grow faster than the company average.
Research Market Dynamics: Research markets are anticipated to remain muted in 2026, consistent with the latter half of 2025, but pricing headwinds are expected to ease as the NovaSeq X transition nears completion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: In Q3, we repurchased approximately 1.24 million shares of Illumina stock at an average price of $97.10 per share for a total of $120 million. At quarter end, we had $684 million remaining on our share repurchase authorization, and we intend to continue to repurchase shares opportunistically.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about China in 2026, and what is the outlook for clinical growth for the full year and 2026?
A:The CEO expressed satisfaction with the performance in China and noted progress in serving OEM partners despite unresolved regulatory issues. However, it is too early to provide a view on 2026. Clinical growth is expected to be a driver, but specific guidance for 2026 was not provided.
Q:Is the framework of low single-digit revenue growth for 2026 reasonable, and what is the margin outlook as the environment normalizes?
A:The CEO acknowledged the framework of clinical growth driving revenue while research remains muted and China being a headwind. However, no specific guidance for 2026 was given. The CFO highlighted ongoing cost structure actions and anticipated further margin expansion through cost optimization and operating leverage.
Q:Was there any pull forward in academic and government segments for consumables growth, and is the 500 basis points of margin expansion still relevant?
A:The CEO stated there was no pull forward in academic and government segments, and consumables growth was driven by clinical demand. The CFO confirmed the 500 basis points margin expansion goal remains relevant, with opportunities for further improvement in gross margins and cost structure.
Q:How are you thinking about multiyear grants and pent-up demand in research, and can you grow earnings in 2026 given China and Roche headwinds?
A:The CEO noted that researchers are cautious due to uncertainty in grant predictability. The company is confident in its ability to grow earnings in 2026 despite headwinds, citing disciplined cost management and operational improvements.
Q:What is the outlook for NovaSeq X placements and the sustainability of 50-60 placements per quarter?
A:The CEO expressed confidence in sustaining the 50-60 placements per quarter trend, noting strong sequencing demand and applications in clinical and research spaces. However, specific guidance for 2026 was not provided.
Q:What is the impact of the competitive environment, including Roche, on 2026 and the clinical market?
A:The CEO welcomed competition and emphasized Illumina's differentiation across multiple dimensions, including quality, workflow, and cost. The company remains confident in its competitive position and ability to innovate.
Q:How sustainable is the clinical consumables growth rate, and are there catalysts for further growth?
A:The CEO highlighted strong clinical consumables growth driven by NovaSeq X placements and new test approvals. The CFO noted momentum in clinical applications like early detection and therapy selection, with potential for continued growth.
Q:What is the outlook for research and applied markets, and how has gigabyte output trended in these segments?
A:The CEO noted that the research and applied markets have transitioned to NovaSeq X, reducing pricing headwinds. Gigabyte output has grown, albeit at a slower rate in research compared to clinical.
Q:What is the outlook for R&D expenses and their impact on competitiveness?
A:The CEO emphasized disciplined R&D spending and improved productivity, with a strong portfolio of innovations expected to drive future growth.
Q:Can you achieve double-digit EPS growth in 2026, and what are the key levers for earnings expansion?
A:The CEO and CFO expressed confidence in achieving EPS growth through disciplined cost management, operational improvements, and leveraging growth opportunities in clinical and research markets.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026 revenue and earnings, citing the need for more clarity on market and regulatory developments. They also used vague language when discussing the predictability of research funding and the impact of competition on market dynamics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASHG
Ankur
BioInsight scale
Conor
Greater China
Illumina
NovaSeq instrument
approval
assay
base
consumables
conversation
conversion
demand
dynamic
end market
insight road
methylation
multiomics
partner
partnership
pillar
prep
pricing headwind
road map
service software
software AI
software capability
solution
term target
throughput
transition
workflow
ILMN Transcript
Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call highlights strong financial performance with a 19% increase in EPS and improved margins. Management expressed optimism about clinical growth and incremental instrument placements, despite not raising organic growth guidance. The Q&A section reassures strong demand and no market freezing, with expectations of margin improvements later in the year. Although some vague responses were noted, the overall sentiment is positive with raised guidance and strategic growth in clinical and spatial markets.
Illumina, Inc. (ILMN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call summary and Q&A indicate strong financial performance with 16% EPS growth and improved margins. Despite challenges in Greater China, the overall growth outlook is optimistic, especially with high single-digit revenue growth and strategic transitions like NovaSeq X. The Q&A reveals confidence in achieving long-term targets and strong demand in clinical markets. The lack of detailed M&A criteria and cautious guidance for 2026 are minor concerns, but the positive aspects outweigh these, suggesting a positive stock price movement.
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
ILMN Slides
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances2026-02-05
Illumina Q2 2025 slides: Revenue dips 3% while EPS grows 9% amid NovaSeq X transition2025-10-30
Illumina Q2 2025 slides: revenue declines 3% while margins expand, SomaLogic acquisition announced2025-07-31
Illumina Q1 2025 slides: Revises guidance downward amid China restrictions and tariff impacts2025-05-08
ILMN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
